We are using cookies This website uses cookies in order to offer you the most relevant information. By browsing this website, you accept these cookies.
In conclusion, further investigation of etoposide in malignant mesothelioma is not recommended.
2
Seric values have been evaluated in 24 patients receiving high doses of etoposide.
3
Patients in group A did not receive either MTX or etoposide.
4
Six patients had been treated with concurrent cisplatin and etoposide plus chest x-ray.
5
One cell line resistant to etoposide-induced apoptosis failed to show degradation of DNA-PKcs.
1
Intravenous and oral etoposide ( VP 16-213) were tested in two sequential phase II trials in chemotherapy-naive patients with malignant pleural mesothelioma.
1
The neoplasm subsequently metastasized and required additional VP-16 and carboplatin for control.
2
Cisplatin and VP-16 combination can be considered as a salvage treatment in heavily pretreated patients with advanced breast cancer.
3
Fas-FasL system participated in the apoptosis induced by DEX and VP-16; different drugs induce apoptosis by different pathway of signal transduction.
4
Chromatin condensation was morphologically evident only when cells detached from the monolayer; untreated or VP-16-treated attached cells retained a normal morphology.
5
This effect was even more pronounced when cells were exposed to VP-16 4 hours before gemcitabine.